« Return to News | R&D Trends | Drug Sponsors

GlaxoSmithKline and Angiochem collaborate on treatments for LSDs

Thursday, March 1, 2012 05:55 AM

Angiochem, a clinical-stage biotechnology company, has partnered with GlaxoSmithKline (GSK) to discover, develop and commercialize treatments for lysosomal storage diseases (LSDs).

The collaboration will combine Angiochem’s expertise in creating novel therapeutics that cross the blood-brain barrier (BBB) with the scientific, development and commercialization capability of GSK in rare diseases. Angiochem initially will create new compounds (EPiC-enzymes) to penetrate the BBB and restore enzyme function in the central nervous system, developing an enzyme replacement therapy for a specified lysosomal storage disease. GSK will have the right to assume responsibility for development and commercialization of the resulting drug candidate. The agreement allows for expansion of the collaboration to include additional lysosomal storage disease targets. 

Angiochem is eligible to receive over $300 million, including up to $31.5 million in upfront cash, research funding and other fees if GSK accesses the few LSD targets available to the collaboration. In addition, Angiochem is eligible to receive royalties on future sales of EPiC-enzymes that arise from the collaboration. 

“This collaboration will further validate the wide-ranging potential for our BBB platform across multiple therapeutic areas and classes of compounds while providing Angiochem with additional resources to advance our own internal pipeline including other EPiC-enzymes,” said Jean-Paul Castaigne, M.D., president and CEO of Angiochem.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.